Revenue

9 Months Ended

Sep. 30, 2021

Revenue

Revenue

3. Revenue

The following table presents the Company’s revenues by Group and End Customer Geography (dollars in millions):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2021			2020			2021			2020
Revenue by Group:
Bruker BioSpin	$	186.5		$	152.1		$	494.4		$	398.1
Bruker CALID		194.2			171.3			579.9			444.5
Bruker Nano		174.9			147.1			504.6			392.7
BEST		57.0			43.8			166.0			134.8
Eliminations		(3.7	)		(2.9	)		(10.5	)		(10.1	)
Total revenue	$	608.9		$	511.4		$	1,734.4		$	1,360.0
	Three Months Ended September 30,						Nine Months Ended September 30,
	2021			2020			2021			2020
Revenue by End Customer Geography:
United States	$	163.2		$	120.1		$	442.0		$	332.1
Germany		55.5			50.4			186.4			134.9
Rest of Europe		155.4			142.9			459.9			357.7
Asia Pacific		191.6			160.0			525.8			433.3
Other		43.2			38.0			120.3			102.0
Total revenue	$	608.9		$	511.4		$	1,734.4		$	1,360.0

Revenue for the Company recognized at a point in time versus over time is as follows (dollars in millions):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Revenue recognized at a point in time	$	530.8	$	442.2	$	1,503.0	$	1,174.0
Revenue recognized over time		78.1		69.2		231.4		186.0
Total revenue	$	608.9	$	511.4	$	1,734.4	$	1,360.0

Remaining Performance Obligations

Remaining performance obligations represent the aggregate transaction price allocated to a promise to transfer a good or service that is fully or partially unsatisfied at the end of the period. As of September 30, 2021, remaining performance obligations were approximately $2,035.9 million. The Company expects to recognize revenue on approximately 68.4% of the remaining performance obligations over the next twelve months and the remaining performance obligations primarily within one to three years.

Contract Balances

The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets) and deferred revenue, customer deposits and billings in excess of revenue recognized (contract liabilities) on the Company’s unaudited condensed consolidated balance sheets.

Contract assets—Most of the Company’s long-term contracts are billed as work progresses in accordance with the contract terms and conditions, either at periodic intervals or upon achievement of certain milestones. Billing often occurs subsequent to revenue recognition, resulting in contract assets. Contract assets are generally classified as other current assets in the unaudited condensed consolidated balance sheets. The balance of contract assets as of September 30, 2021 and December 31, 2020 was $56.4 million and $41.8 million, respectively.

Contract liabilities—The Company often receives cash payments from customers in advance of the Company’s performance, resulting in contract liabilities. These contract liabilities are classified as either current or long-term in the unaudited condensed consolidated balance sheets based on the timing of when revenue recognition is expected. As of September 30, 2021 and December 31, 2020, the contract liabilities were $400.6 million and $399.4 million, respectively. The increase in the contract liability balance during the nine months ended September 30, 2021 is primarily the result of new performance obligations entered into during the period in addition to delays in instrument installations due to customer facility closures or reduced operations as a result of COVID-19. Approximately $250.5 million of the contract liability balance on December 31, 2020 was recognized as revenue during the nine months ended September 30, 2021.